Early myeloid-derived suppressor cells accelerate epithelial-mesenchymal transition by downregulating ARID1A in luminal A breast cancer

Early myeloid-derived suppressor cells (eMDSCs) are a newly characterized subclass of MDSCs, which exhibit more potent immunosuppressive capacity than classical MDSCs. Previously, we found high eMDSCs infiltration was correlated with poor prognosis of breast cancer, though the regulatory mechanisms have not been fully understood. Here, we constructed a 21-gene signature to evaluate the status of eMDSCs infiltration within breast cancer tissues and found that highly infiltrated eMDSCs affected the prognosis of breast cancer patients, especially in luminal A subtype. We also found that eMDSCs promoted epithelial-mesenchymal transition (EMT) and accelerated cell migration and invasion in vitro. Meanwhile, eMDSCs significantly downregulated ARID1A expression in luminal A breast cancer, which was closely associated with EMT and was an important prognostic factor in breast cancer patients. Moreover, significant changes of EMT-related genes were detected in luminal A breast cancer cells after co-cultured with eMDSCs or ARID1A knock-down and overexpression of ARID1A significantly reversed this procedure. These results implied that eMDSCs might suppress the ARID1A expression to promote EMT in luminal A breast cancer cells, which might provide a new light on developing novel treatment regimens for relapsed luminal A breast cancer after conventional therapies.

[1]  J. Merchant,et al.  The immune microenvironment in gastric adenocarcinoma , 2022, Nature Reviews Gastroenterology & Hepatology.

[2]  Zhijun Sun,et al.  Targeting myeloid-derived suppressor cells for cancer therapy , 2021, Cancer biology & medicine.

[3]  M. Merad,et al.  MDSC: Markers, development, states, and unaddressed complexity. , 2021, Immunity.

[4]  Yi Zhao,et al.  Imbalance of TGF-β1/BMP-7 Pathways Induced by M2-polarized Macrophages Promotes Hepatocellular Carcinoma Aggressiveness. , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  Justin K. Huang,et al.  Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress , 2020, Cancer Research.

[6]  Dong Hoon Kim,et al.  Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma , 2020, Journal of gynecologic oncology.

[7]  Shuang Gao,et al.  Role of ARID1A in epithelial-mesenchymal transition in breast cancer and its effect on cell sensitivity to 5FU , 2020, International journal of molecular medicine.

[8]  T. Efferth,et al.  Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. , 2020, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[9]  Rui Zhang,et al.  Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer , 2020, Oncogene.

[10]  Zhihua Liu,et al.  ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness , 2019, Cell Death & Differentiation.

[11]  Hui Shen,et al.  ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion , 2019, Nature Communications.

[12]  L. Shevde,et al.  The Tumor Microenvironment Innately Modulates Cancer Progression. , 2019, Cancer research.

[13]  Xiaosheng Wang,et al.  ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer , 2019, Cells.

[14]  C. Blanpain,et al.  EMT Transition States during Tumor Progression and Metastasis. , 2019, Trends in cell biology.

[15]  Shengjun Wang,et al.  MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation , 2019, Front. Immunol..

[16]  Junbo Hu,et al.  M2 Macrophage-Derived Exosomes Promote Cell Migration and Invasion in Colon Cancer. , 2018, Cancer research.

[17]  R. Weinberg,et al.  New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer , 2018, Nature Reviews Molecular Cell Biology.

[18]  B. Taylor,et al.  The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.

[19]  Qi Wang,et al.  CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-κB/SOX4 signaling , 2018, Cell Death & Disease.

[20]  Rui Zhang,et al.  SOCS3 Suppression Promoted the Recruitment of CD11b+Gr-1−F4/80−MHCII− Early-Stage Myeloid-Derived Suppressor Cells and Accelerated Interleukin-6-Related Tumor Invasion via Affecting Myeloid Differentiation in Breast Cancer , 2018, Front. Immunol..

[21]  G. Mills,et al.  ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade , 2018, Nature Medicine.

[22]  B. Baradaran,et al.  Myeloid‐derived suppressor cells: Important contributors to tumor progression and metastasis , 2018, Journal of cellular physiology.

[23]  V. Mittal.  Epithelial Mesenchymal Transition in Tumor Metastasis. , 2018, Annual review of pathology.

[24]  Rui Zhang,et al.  Interleukin-6 Trans-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells via Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer , 2017, Front. Immunol..

[25]  Janet Iwasa,et al.  Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes , 2017, Nature Reviews Molecular Cell Biology.

[26]  R. Weinberg,et al.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.

[27]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[28]  J. Carroll.  Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer , 2016, European journal of endocrinology.

[29]  J. Tyson,et al.  Endocrine resistance in breast cancer – An overview and update , 2015, Molecular and Cellular Endocrinology.

[30]  J. Gustafsson,et al.  Estrogen receptor mutations and functional consequences for breast cancer , 2015, Trends in Endocrinology & Metabolism.

[31]  Hui Li,et al.  Noncanonical NF-κB Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer , 2014, The Journal of Immunology.

[32]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[33]  M. Larsen,et al.  Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer , 2013, Breast Cancer Research and Treatment.

[34]  Kathleen R. Cho,et al.  Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. , 2013, Immunity.

[35]  Juntian Liu,et al.  Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer , 2013, The Journal of Immunology.

[36]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[37]  Pieter Wesseling,et al.  The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells , 2013, Immunology.

[38]  Jean Paul Thiery,et al.  Early events in cell adhesion and polarity during epithelial-mesenchymal transition , 2012, Journal of Cell Science.

[39]  J. Gustafsson,et al.  The different roles of ER subtypes in cancer biology and therapy , 2011, Nature Reviews Cancer.

[40]  C. Divino,et al.  Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. , 2011, Immunity.

[41]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[42]  Q. Cui,et al.  Identification of high-quality cancer prognostic markers and metastasis network modules , 2010, Nature communications.

[43]  C. Divino,et al.  Development and Function of Myeloid‐Derived Suppressor Cells Generated From Mouse Embryonic and Hematopoietic Stem Cells , 2010, Stem cells.

[44]  A. Onitilo,et al.  Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.

[45]  Franck Molina,et al.  A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer , 2008, Clinical Cancer Research.

[46]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[47]  S. Akira,et al.  IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages , 2003, Nature Immunology.